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Background: S100 family proteins have recently been identified as biomarkers in various cancers. Of this protein
family, S100A14 and S100A16 are also believed to play an important role in tumor progression. The aim of the
present study was to clarify the clinical significance and functional role of these molecules in breast cancer.
Methods: In a clinical study, an immunohistochemical analysis of S100A14 and S100A16 expression in archival
specimens of primary tumors of 167 breast cancer patients was performed. The relationship of S100A14 and S100A16
expression to patient survival and clinicopathological variables was statistically analyzed. In an experimental study, the
subcellular localization and function of these molecules was examined by using the human breast cancer cell lines
MCF7 and SK-BR-3, both of which highly express S100A14 and S100A16 proteins. Cells transfected with expression
vectors and siRNA for these genes were characterized using in vitro assays for cancer invasion and metastasis.
Results: Immunohistochemical analysis of 167 breast cancer cases showed strong cell membrane staining of S100A14
(53% of cases) and S100A16 (31% of cases) with a significant number of cases with co-expression (p < 0.001). Higher
expression levels of these proteins were significantly associated with a younger age (<60 years), ER-negative status,
HER2-positive status and a poorer prognosis. Co-expression of the two proteins showed more aggressive features with
poorer prognosis. In the human breast cancer cell lines MCF7 and SK-BR-3, both proteins were colocalized on the cell
membrane mainly at cell-cell attachment sites. Immunoprecipitation and immunofluorescence analyses demonstrated
that the 100A14 protein can bind to actin localized on the cell membrane in a calcium-independent manner. A Boyden
chamber assay showed that S100A14 and S100A16 knockdown substantially suppressed the invasive activity of both
cell lines. Cell motility was also inhibited by S100A14 knockdown in a modified dual color wound-healing assay.
Conclusions: To our knowledge, this is the first report showing the correlation of expression of S100A14, S100A16, and
co-expression of these proteins with poor prognosis of breast cancer patients. In addition, our findings indicate that
S100A14 and S100A16 can promote invasive activity of breast cancer cells via an interaction with cytoskeletal dynamics.
S100A14 and S100A16 might be prognostic biomarkers and potential therapeutic targets for breast cancer.
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Breast cancer is the leading cause of cancer mortality in
women worldwide [1]. Significant advances in early de-
tection and molecular-based treatments have improved
breast cancer patient survival. Further understanding of
the molecular mechanism of breast cancer progression
would produce new biomarkers for the precise prediction
of patient prognosis and for molecular targeted-therapy.
We have focused on the detection of novel biomarkers of
cancer progression including of invasion and metastasis
based on experimental studies [2] and have identified the
S100 family proteins S100A14 and S100A16 as important
candidate molecules for the regulation of metastatic
disease.
S100 proteins belong to a large subgroup of 25 small,
acidic proteins that are characterized by distinctive homo-
or hetero-dimeric architecture and EF hand Ca2+-binding
motifs, and which are expressed in a variety of cell types.
S100 proteins have a broad range of intracellular functions
that are exerted through the modulation of their subcellu-
lar localization and interactions with specific target pro-
teins responsible for cell growth, differentiation, motility,
and cell-cycle regulation [3]. S100 proteins have recently
become of great interest because of their close association
with inflammation, neurodegenerative disorders and can-
cer [4,5].
S100A14, which was isolated by analysis of a human
lung cancer cell line, is differentially expressed in a var-
iety of cell types, in both normal and neoplastic tissues.
S100A14 expression is up-regulated in cancers of the
lung, breast, and uterus, whereas it is down-regulated in
tumors of the colon, kidney, and rectum [6]. The over-
expression of S100A14 was correlated with poorer prog-
nosis in breast cancer and liver cancer [7-9], while it was
correlated with favorable prognosis in colorectal and
small intestinal cancers [10,11]. Several studies suggest
that S100A14 affects cell proliferation, invasion and mo-
tility through interactions with HER2, MMP2, P53 and
receptor for advanced glycation end products (RAGE)
[9,12-15]. However, to date, the mechanism of its cell
membrane localization and the precise role of S100A14
in human cancer remain unclear and controversial.
S100A16, a novel member of the S100 family that was
isolated from an astrocytoma, has been proposed to be a
binding partner of S100A14 [16,17]. S100A16 is ubiqui-
tously expressed and is elevated in various tumors [18].
S100A16 is potentially relevant to malignancy. However,
the physiological and pathological roles of S100A16, es-
pecially its roles in cancer, are largely unknown.
The first aim of the present study was to investigate
the clinical significance of S100A14 and S100A16 ex-
pression in the prognosis of breast cancer patients. We
analyzed the correlation of their protein expression with
the prognosis of 167 breast cancer patients using animmunohistochemical method. The second aim was to
explore the molecular mechanisms by which S100A14
and S100A16 contribute to the progression of breast
cancer. We investigated the interactions of S100A14,
S100A16 with other binding protein(s) in breast cancer
cells and examined the function of these molecules in
cellular proliferation, migration and invasion.Methods
Patients and samples
The analysis of human tissues was approved by the
Human Research Ethical Committee of Fukushima
Medical University (No. 1203). Tissue samples from 167
patients who underwent surgical resection for primary in-
vasive breast cancer at Fukushima Medical University
Hospital from January 1990 to December 1996 were col-
lected. After surgery, most patients were treated with the
standard practice guidelines at that time and have been
followed up regularly. Formalin-fixed, paraffin-embedded
materials were used for routine staining with hematoxylin
and eosin and for staining by immunohistochemical
techniques.Immunohistochemical analysis
Rabbit polyclonal antibodies for S100A14 (Acris) and
S100A16 (Proteintech) were used for this study. Specificity
of the antibodies was determined by two methods. One
method was an absorption test using S100A14 (Abcam)
and S100A16 (Proteintech) recombinant proteins, in
which the signal of each protein was diminished by the
absorbed antibody in both immunohistochemistry and
Western blotting (Additional file 1: Figure S1). Another
method was an immunofluorescence study using MCF7, a
human breast cancer cell line, which was transfected with
the S100A14 or S100A16 expression vector described
below, in which an increased signal for each protein on
the cell membrane was detected using an immunofluores-
cence method with an antibody to each protein (data not
shown). Immunostaining was performed by using an
indirect streptavidin-biotin immunoperoxidase method
(SAB-PO (M) kit, Nichirei Corp.). After antigen retrieval
in a microwave oven for 15 min in 10 mM citrate buffer
(pH 9.0 for S100A14 and pH 6.0 for S100A16), en-
dogenous peroxidase activity was blocked with a 3%
H2O2-methanol solution. The slides were incubated
with primary antibodies (diluted 1/100) overnight at 4°C,
washed with PBS, and then incubated with secondary
biotin-labeled antibodies for 30 min at room temperature.
Antibody localization was visualized with peroxidase-
conjugated streptavidin for 30 min at room temperature,
followed by the diaminobenzidine reaction. The slides
were counterstained with hematoxylin.
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The human breast cancer cell lines MCF7, ZR75-1, SK-
BR-3 and MDA-MB-231 were purchased from the Ameri-
can Type Culture Collection. The cells were cultured in
DMEM (MCF7 and SK-BR-3 cells) or RPMI1640 (ZR75-1
and MDA-MB231 cells) supplemented with 10% fetal
bovine serum (FBS). Three-dimensional (3D) cultures of
multicellular spheroids of MCF7 cells were grown in 8-
well chamber slides (BD Biosciences) using a type I col-
lagen gel (KOKEN) according to the manufacturer’s
protocol (KOKEN). In order to determine whether the
localization of S100A14 and S100A16 proteins is calcium-
dependent or not, cells were incubated with 10 mM
EGTA according to a previous method [19].Construction of S100A14 and S100A16 expression vectors
and transfection
cDNA expression vectors for the human S100A14 and
S100A16 genes were constructed by PCR amplification of
their coding regions using cDNAs derived from MCF7
cells as templates and specific primers, followed by clon-
ing of the genes into a pEGFP expression vector (Takara-
Clontech, Shiga, Japan). The primer sequences used for
PCR were, S100A14 forward: 5′-atgggacagtgtcggtcagc-
caacgca-3′, reverse: 5′-acccatgagctccccagagcatccaagac-3′
and S100A16 forward: 5′-agcagggagatgtcagactgctacacgga-
3′, reverse: 5′-aggtgtggccaaaggggtctctagctg-3′. Specificity
of these primers was determined by a homology search
(Standard Nucleotide BLAST, NCBI). The constructed.
plasmids containing S100A14 and S100A16 tagged with
GFP, and the empty vectors of pEGFP-N1 and ptdTomato-
N1 (Takara-Clontech), were introduced into MCF7
cells by using the FuGENE transfection reagent (Roche)
according to the manufacturer’s protocol. To establish
stable transfectants, selection of the cells was started
48 hours after transfection in 6-well plates with G418
antibiotics (0.8 mg/ml, Promega). Resistant cells were
cloned by the single cell cloning method after 3 weeks
of selection.RNA interference transfection
Stealth RNAi targeted to human S100A14 and S100A16,
and RNAi negative control (Life Technologies) were
used for RNAi experiments. Three sets of siRNAs with
different sequences for each mRNA were purchased. For
reverse transfection, 6 pmol RNAi duplexes were diluted
in 0.1 ml Opti-MEM medium in each well of a 24-well
plate. One μl Lipofectamine MAX reagent (Life Technolo-
gies) was added to the well. After 10 min incubation,
0.5 ml of MCF7 or SK-BR-3 cells (2 × 105 cells /ml) were
added to each well in DMEM with 10% FBS. The gene
knockdown efficiency of RNAi was determined by im-
munofluorescence microscopy with anti S100A14 andS100A16 antibodies (Acris) (Additional file 2: Figure S2).
The most effective siRNAs were used for the following ex-
perimental studies. The sequences of the siRNAs that
were ultimately selected were: S100A14; 5′-GAGUUC
AGGAGUUUCUGGGAGCUGA-3′ and S100A16; 5′-CC
AAUCAUGAUGGGCGCAUCAGCUU-3′. The detection
primers were: S100A14 forward; 5′-atgggacagtgtcggtcagc
caacgca-3′, reverse; 5′-aggcccacagtctctccccaacaccc-3′,
S100A16 forward; 5′-cagggagatgtcagactgctacac-3′, reverse;
5′-catcaggccagtgcctggaa-3′. The specificity of these siR-
NAs and primers was determined by a homology search
(Standard Nucleotide BLAST, NCBI).In vitro invasion assay
A cell invasion assay was performed in BioCoat cell cul-
ture inserts with a polystyrene membrane (8-μm pore;
BD Bioscience) in a 24-well tissue culture plate. The cul-
ture insert was coated with Matrigel (BD Bioscience,
8.7 μg per chamber); the lower chamber was filled with
DMEM containing 10% serum. A total of 4 × 105 MCF7
cells or 1 × 105 SK-BR-3 cells were seeded in the upper
chamber containing DMEM with 10% serum and the
cells were incubated at 37°C for 24 h. After wiping off
the cells on the upper side, the membrane was removed
and stained with Giemsa solution. The cells that had mi-
grated to the lower side of the membrane were counted
under a microscope.Wound healing assay and dual-color wound healing assay
To visualize the effect of transfected RNAi targeted
against S100A14 and S100A16 on the motility of living
cells, we performed two types of wound healing assays,
the standard method and a modified dual-color wound
healing assay. For the standard assay, a distinct area of
the cell layer of a monolayer culture of MCF7 cells,
which were transiently transfected with S100A14 and
S100A16 siRNAs or with negative control siRNA, was
wounded using a micropipette tip. The distance over
which the cells had migrated into the wounded areas fol-
lowing 48 h incubation at 37°C was evaluated under a
microscope. For the modified assay, we used MCF7
stable transfectants that were labelled with either green
or red fluorescence and were additionally transfected
with gene-specific siRNA or control siRNA, respectively.
MCF7 cells that were stably transfected with either
pEGFP (green) or ptdTomato (red) (Takara-Clontech)
were first constructed as described above. Each trans-
fectant was then further transfected with Stealth RNAi
for human S100A14 or RNAi negative control, respect-
ively. These green and red fluorescent cells were then
mixed in equal numbers and plated at a density of 1×105
cells per well in a 24-well tissue culture plate. After
48 h, a distinct area of the monolayer culture was
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the scratched region over a period from 0 to 48 h were
recorded by using a phase-contrast fluorescent micro-
scope (Olympus).
Immunoprecipitation
Protein extracts from MCF7 cells were prepared using
HEPES buffer containing 1% NP-40. To determine
whether the binding between S100A14 protein and actin
is calcium-dependent or not, 0 or 2 mM CaCl2, or,
2 mM CaCl2 and 10 mM EDTA were added to the ex-
tracts. Rabbit anti-S100A14 antibody (diluted 1/100),
anti-actin antibody (diluted 1/100) or normal rabbit IgG
as the IP control (Sigma-Aldrich, St. Louis, USA) was
applied to Protein A Sepharose beads (GE Healthcare)
suspended in PBS-buffer and incubated for 2 h at room
temperature. To cross-link antibodies to the beads,
DMP (dimethyl pimelimidate dihydrochloride) in bor-
acic acid was added and incubated for 30 min at room
temperature. After washing with 0.1 M glycine-HCl
(pH 2.8) to remove unbound antibody, the beads were
incubated with protein extracts overnight at 4°C. The
beads were washed with HEPES buffer, and protein was
eluted with 0.1 M glycine-HCl (pH 2.0) for 1 h on ice.
Immunofluorescence and western blot analyses
Cultured cells were plated on 8-well chamber slides for
24 to 48 h. Cells were fixed with 4% paraformaldehyde
and permeabilized for 5 min at room temperature with
0.1% Triton X-100 in PBS, followed by blocking for 1 h
with 5% skimmed milk. Cells were stained with rabbit
polyclonal antibodies for S100A14 and S100A16 for
overnight at 4°C, followed by incubation with FITC-
labeled secondary antibody for 1 h at room temperature.
To observe filamentous actin, cells were stained with
rhodamine-conjugated phalloidin (Molecular Probes).
The slides were mounted in mounting medium containing
DAPI and analyzed using an inverted fluorescence micro-
scope and by laser scanning confocal microscopy. Cellular
proteins extracted with Cell lysis reagent (Sigma) were an-
alyzed by Western blotting. Equal amounts of proteins
were electrophoresed by standard SDS-PAGE under redu-
cing conditions and were then transferred onto Immobi-
lon membranes (Merck-Millipore). The target proteins
were detected by immunoblotting using S100A14 and
S100A16 antibodies (diluted 1/1,000) according to stand-
ard protocols using the ECL Advance Western Blotting
Detection Kit (GE Healthcare).
Statistical analysis
SPSS 17.0 statistical software (SPSS Inc.) was used for all
statistical analyses. The χ2 test with Yates correction and
Fisher’s exact test were used to examine the relationshipbetween S100A14 or S100A16 expression and clinicopath-
ological variables. The receiver operating characteristics
(ROC) curve was constructed to determine diagnostic
specificity and sensitivity. The cumulative survival rate
was calculated by the Kaplan-Meier method and statistical
significance was examined by the log-rank test. Evaluation
of the prognostic significance of the clinicopathological
factors was performed by univariate and multivariate re-
gression techniques (Cox’s proportional hazards model).
Statistical significance was determined as p < 0.05.Ethical statement
The analysis of human tissues was approved by the
Human Research Ethical Committee of Fukushima Med-
ical University (registration number 1203). Written in-
formed consent was obtained from the patients for the
publication of this report. This investigation conformed
to the principles outlined in the Helsinki Declaration.Results
Evaluation of S100A14 and S100A16 protein expression
in breast cancer cells
At first, we immunohistochemically screened S100A14
and S100A16 expression in normal and neoplastic cells of
each organ (Additional file 3: Figure S3). They were
ubiquitously expressed in a variety of expression level
and localization, while squamous epithelium strongly
expressed these proteins on the cell membrane. To de-
termine the contribution of S100 protein expression to
breast cancer, we first used immunohistochemistry to
analyze S100A14 and S100A16 protein expression in
tissue samples of 167 patients who underwent surgical
resection for primary invasive breast cancer. This ana-
lysis revealed that S100A14 and S100A16 proteins were
expressed mainly on the membrane of breast cancer
cells, while no or faint staining was seen in normal epi-
thelial cells of each sample (Figure 1A, representative
staining). Immunoreactivity was evaluated using a semi-
quantitative scoring method that was based on determin-
ation of the proportion of positive tumor cells and the
staining intensity. With regard to the staining intensity,
tumor cells that showed staining of the entire membrane
that was as strong as the positive control epidermal squa-
mous epithelium in the same patient, was determined
intensity score 2, weaker staining than the control was
intensity score 1 and negative staining was considered
intensity score 0. The expression levels of S100A14 and
S100A16 in tumors were scored by multiplying the per-
centage of positively stained cells by the intensity score.
ROC curves were plotted and analyzed to determine
the optimal cut-off values of S100A14 and S100A16
scores. S100A14 and S100A16 showed statistically signifi-
cant AUCs of 0.660 (P = 0.002) and 0.643 (P = 0.005). A
Figure 1 S100A14 and S100A16 expression in normal and cancerous breast tissues. A, Representative images of S100A14 and S100A16
protein expression in normal or cancerous breast cancer tissue that was examined using immunohistochemistry. No or faint signals from these
proteins were detected in normal epithelial cells of the breast, whereas both proteins were strongly expressed along the cell membrane in about
half of breast cancer tissues. B, Kaplan–Meier survival analysis of breast cancer patients. Kaplan–Meier survival curves for patients according to the
levels of S100A14 and S100A16 expression are shown.
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was the optimal value for maximum sensitivity and speci-
ficity, and these values were therefore selected as the cut-
off score.S100A14 and S100A16 expression and clinicopathological
factors of breast cancers
We then correlated the expression of S100A14 and
S100A16 proteins with clinicopathological factors (Table 1).
Both S100A14 positivity and higher S100A16 expres-
sion were significantly associated with younger patient
age (<60 years old, P = 0.041 and 0.046, respectively),
ER-negative status (P = 0.014 and 0.030, respectively)
and HER2-positive status (P = 0.001 and < 0.001. re-
spectively), whereas higher S100A16 expression was
also significantly associated with tumor size (P = 0.007)
and lymph node metastasis (P < 0.001). Furthermore,
there was a positive correlation between S100A14expression and S100A16 expression (P < 0.001). Co-
expression of S100A14 and S100A16 was correlated
with younger patient age (<60 years old, P = 0.025),
lymph node metastasis (P = 0.005), ER-negative status
(P = 0.008) and HER2-positive status (P < 0.001).Expression of S100A14 and S100A16 predicts the
prognosis of breast cancer patients
To analyze the correlation between S100A14 and
S100A16 expression with the prognosis of breast cancer
patients, Kaplan-Meier survival curves were generated.
During the follow-up of 147 patients, 99 patients (67%)
survived for 10 years. High positive expression of each
protein was correlated with poor outcome (S100A14,
P = 0.0002; S100A16, P = 0.0075, Figure 1B). Double-
positive cases that expressed both proteins showed the
worst prognosis (P = 0.0005). In multivariate analysis,
S100A14 expression (P < 0.001), PgR (P = 0.024) and
Table 1 Association between clinicopathological variables and S100A14 and S100A16













n = 84 (%) n = 83 (%) n = 132 (%) n = 35 (%) n = 137 (%) n = 30 (%)
Patient age (y)
<60 53(31.7) 65(38.9) 0.047* 88(52.7) 30(18.0) 0.046* 93(55.7) 25(15.0) 0.025*
≥60 31(18.6) 18(10.8) 44(26.3) 5(3.0) 44(26.3) 5(3.0)
pT
1 29(17.4) 20(12.0) 0.183 46(27.5) 3(1.8) 0.007§ 47(28.1) 2(1.2) 0.07
2 49(29.3) 52(31.1) 73(43.7) 28(16.8) 77(46.1) 24(14.4)
3 6(3.6) 8(4.8) 11(6.6) 3(1.8) 11(6.6) 3(1.8)
4 0(0) 3(1.8) 2(1.2) 1(0.6) 2(1.2) 1(0.6)
pN
0 30(18.0) 22(13.2) 0.153 51(30.5) 1(0.6) <0.001§ 51(30.5) 1(0.6) 0.005§
1 50(29.9) 50(29.9) 71(42.5) 29(17.4) 76(45.5) 24(14.4)
2 4(2.4) 10(6.0) 10(6.0) 4(2.4) 10(6.0) 4(2.4)
3 0(0) 1(0.6) 0(0) 1(0.6) 0(0) 1(0.6)
TNM staging
I 25(15.0) 15(9.0) 0.126 37(22.2) 3(1.8) 0.067 37(22.2) 3(1.8) 0.214
II 50(29.9) 50(29.9) 75(44.9) 25(15.0) 80(47.9) 20(12.0)
III 8(4.8) 14(8.4) 16(9.6) 6(3.6) 16(9.6) 6(3.6)
IV 1(0.6) 4(2.4) 4(2.4) 1(0.6) 4(2.4) 1(0.6)
Histological grade
1 26(15.6) 13(7.8) 0.069 33(19.8) 6(3.6) 0.433 36(21.6) 3(1.8) 0.147
2 36(21.6) 43(25.7) 63(37.7) 16(9.6) 65(38.9) 14(8.4)
3 22(13.2) 27(16.2) 36(21.6) 13(7.8) 36(21.6) 13(7.8)
ER
Negative 23(13.8) 39(23.4) 0.014* 43(25.7) 19(11.4) 0.030* 44(26.3) 18(10.8) 0.008*
Positive 61(36.5) 44(26.3) 89(53.3) 16(9.6) 93(55.7) 12(7.2)
PgR
Negative 53(31.9) 50(29.9) 0.826 80(47.9) 23(13.8) 0.721 83(49.7) 20(12.0) 0.618
Positive 31(18.7) 33(19.9) 52(31.1) 12(7.2) 54(32.3) 10(6.0)
HER2
score 0 & 1 76(45.4) 56(33.1) 0.001* 114(68.3) 18(10.8) <0.001* 118(70.7) 14(8.4) <0.001*
score 2 & 3 8(4.9) 27(16.6) 18(10.8) 17(10.2) 19(11.4) 16(.96)
S100A16
low 79(47.3) 53(31.7) <0.001*
high 5(3.0) 30(18.0)
*p <0.05 for χ2 test with Yates correction.
§p <0.05 for Fisher’s exact test.
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nostic value for overall survival (Table 2B). Further-
more, when defined as a single factor, co-expression of
S100A14 and S100A16 was determined as an independ-
ent prognostic factor (P = 0.001) (Table 2C).S100A14 and S100A16 expression in human breast cancer
cell lines
To further analyze the role of S100A14 and S100A16
proteins in breast cancer, we next examined the mRNA
expression levels of S100A14 and S100A16 in human
Table 2 Univariate and multivariate analysis of overall survival in breast cancer patients
A. Univariate analysis
Parameter P Hazard ratio 95% CI
S100A14 (positive vs negative) <0.001 3.315 1.777 to 6.813
S100A16 (positive vs negative) <0.001 2.947 1.640 to 5.927
Co-expression of S100A14 and S100A16 (yes vs no) <0.001 3.678 2.029 to 6.666
Age (<60 vs ≥ 60 years) 0.475 0.788 0.660 to 2.439
Tumor size (≥2 cm vs < 2 cm) 0.852 1.060 0.576 to 1.951
Lymph node metastasis (yes vs no) <0.001 2.746 1.770 to 4.261
ER (negative vs positive) 0.003 2.351 1.333 to 4.143
PgR (negative vs positive) 0.040 1.948 1.030 to 3.685
HER2 score (2,3 vs 0,1) <0.001 2.680 1.492 to 4.815
Histological grade (3 vs 1,2) <0.001 4.782 2.653 to 8.618
NS: not significant
B. Multivariate analysis including each S100A14 and S100A16 expression
Parameter P Hazard ratio 95% CI
S100A14 (positive vs negative) <0.001 3.397 1.807
S100A16 (positive vs negative) NS
Age (<60 vs ≥ 60 years) NS
Tumor size (≥2 cm vs < 2 cm) NS
Lymph node metastasis (yes vs no) NS
ER (negative vs positive) NS
PgR (negative vs positive) 0.024 2.107 1.104 to 4.021
HER2 score (2,3 vs 0,1) NS
Histological grade (3 vs 1,2) <0.001 4.316 2.383 to 7.817
NS: not significant
C. Multivariate analysis including coexpression of S100A14 and S100A16
Parameter P Hazard ratio 95% CI
Co-expression of S100A14 and S100A16 (yes vs no) 0.001 2.811 1.529 to 5.170
Age (<60 vs ≥ 60 years) NS
Tumor size (≥2 cm vs < 2 cm) NS
Lymph node metastasis (yes vs no) NS
ER (negative vs positive) NS
PgR (negative vs positive) 0.049 1.907 1.004 to 3.623
HER2 score (2,3 vs 0,1) NS
Histological grade (3 vs 1,2) <0.001 3.970 2.175 to 7.247
NS: not significant
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3 and ZR-75-1 cells expressed both transcripts at high
levels, whereas MDA-MB-231 cells expressed only
S100A16 mRNA (Figure 2A). Immunofluorescence stain-
ing also demonstrated strong expression of S100A14 and
S100A16 proteins on the cell membrane of MCF7, SK-
BR-3 and ZR-75-1 cells. However, MDA-MB-231 cells
did not express either S100A14 or S100A16 proteins
(Figure 2B).Subcellular localization of S100A14 in MCF7 cells
Since cellular localization of S100 proteins is important
for their function, we performed a detailed analysis of the
subcellular localization of S100A14 and S100A16 proteins
in breast cancer cells. For this study we performed im-
munofluorescence staining of MCF7 cells, which ex-
hibit distinct polarity. Under an adherent condition,
these proteins showed a polarized localization in the cell.





























A. mRNA expression (qRT-PCR)
C. Subcellular localization (MCF7)
S100A14 S100A16
S100A14
0 min 60 min 180 min
D. Immunofluolescence under permeable condition (MCF7)
E. S100A14 localization under calcium deficient condition (MCF7)
Figure 2 Expression and localization of S100A14 and S100A16 in human breast cancer cell lines. A, Relative mRNA expression levels measured
by real-time RT-PCR. Expression levels were normalized to β-actin levels within the same sample. B, Protein expression of S100A14 and S100A16.
Expression levels and subcellular localization were visualized using immunofluorescence staining. Scale bar; 50 μm. C, Subcellular localization of
the S100A14 protein on the cell membrane. Z-axis images of confluent MCF7 cells were constructed using confocal laser scanning microscopy.
Scale bar; 10 μm. D, Effect of omission of cell permeabilization on the immunofluorescent staining of S100A14. Following fixation with 4%
paraformaldehyde, the cells were treated with or without 0.1% Triton X-100 in PBS prior to staining. Scale bar; 50 μm. E, Ca2-independent localization
of S100A14 on the cell membrane. MCF7 cells transfected with the S100A14-GFP expression vector were observed by fluorescence microscopy over
180 min after addition of 10 mM EGTA in PBS. Scale bar; 50 μm.
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S100A16 proteins was polarized to the lateral but not to
the basal or the apical regions of MCF7 cells (Figure 2C).
Time-lapse observation of MCF7 cells transfected with the
S100A14-GFP expression vector showed that the protein
was static at the cell-cell attachment sites, but it wasdynamically moving in waves at the leading edge of the
migrating cells (Additional file 4: Video S1). This cell
membrane staining using anti-S100A14 and-S100A16
antibodies was mostly undetectable if Triton X-100 pre-
treatment of the cells, which allows the antibodies to
permeate the membrane, was omitted, indicating that
Tanaka et al. BMC Cancer  (2015) 15:53 Page 9 of 14these proteins are localized at the cytoplasmic side of
the cell membrane (Figure 2D). Time-course observa-
tion of MCF7 cells transfected with the S100A14-GFP
expression vector under a calcium-deficient culture
condition, which was created using 10 mM EGTA in
PBS, showed stable localization of S100A14 on the cell
membrane for 180 min without loss of cell viability
(Figure 2E), indicating that the membrane localization
of S100A14-GFP was calcium independent.Binding of S100A14 to actin
To determine if S100A14 binds to actin, we performed a
pull-down assay of cell extracts of MCF-7 cells using the
anti-S100A14 antibody. Binding of S100A14 to actin was
detected by Western blotting of the S100A14 immunopre-
cipitates using specific antibodies (Figure 3A). Though
interaction between S100A14 and actin was decreased
when 5 mM of EDTA was used along with 2 mM of
CaCl2, we coud not detect increased immunoprecipitation
of actin with increasing Ca2+ concentrations (0.5 and
2 mM of CaCl2). Reverse immunoprecipitation assay
using specific antibody for actin could not detected the
interaction between S100A14 and actin. Immunofluores-
cence analysis demonstrated colocalization of S100A14
and actin in a linear pattern on the membrane at the cell-
cell attachment sites (Figure 3B). Immunofluorescence
staining of MCF7 cells transfected with the S100A14-GFP
expression vector using S100A16 antibody showed coloca-
lization of S100A14 and S100A16 proteins on the cell
membrane of MCF7 cells (Figure 3B), although the bind-
ing of these proteins to each other was not demonstrated
in the pull-down assay (data not shown).Functional interaction of S100A14 with S100A16
We examined potential S100A14 and S100A16 Functional
interaction by using siRNA-based knockdown methods.
Either S100A14 or S100A16 targeted siRNA inhibited
the mRNA expression of its specific target transcript
but did not affect the mRNA expression of the other
gene (Figure 3C). At the protein level, Western blot ana-
lysis indicated that knockdown of S100A14 or S100A16
slightly reduced expression of the other protein, but mark-
edly decreased expression of the target protein (Figure 3D).
In contrast, immunofluorescence analysis showed that
knockdown of S100A14 or S100A16 with their specific
siRNAs markedly decreased not only the presence of their
target protein on the cell membrane but also the presence
of the other protein on the cell membrane (Figure 3E).
These experiments suggested that the presence of both
proteins is required for the localization of each protein to
the cell membrane but that the expression of each protein
is independent of the other.S100A14 and S100A16 promote cellular invasion
To analyze the functional roles of S100A14 and S100A16
in cancer cells, we examined the cellular behavior of
MCF7 and SK-BR-3 cells transfected with S100A14 and
S100A16 specific siRNAs. Knockdown of S100A14,
S100A16 or of both proteins, all slightly inhibited
in vitro cellular proliferation, which was statistically not
significant (Additional file 5: Figure S4). Furthermore,
knockdown of S100A14 or S100A16 suppressed cellular
invasiveness in three assay systems. In the first system,
we examined the cellular invasiveness of MCF7 and
SK-BR-3 cells by using an in vitro invasion assay with a
Matrigel-coated culture insert. Knockdown of S100A14
or S100A16 reduced the number of cells that migrated
through 8 μm-sized pores (Figure 4A). The second sys-
tem that we used consisted of two different wound
healing assays that evaluated the effect of S100A14 or
S100A16-knockdown on the movement of MCF7 cells.
In the standard assay, S100A14 knockdown signifi-
cantly suppressed cell motility, while motility was not
inhibited by S100A16 knockdown (Figure 4B). To con-
firm the inhibitory activity of S100A14 knockdown on
cell movement, we performed a dual-color wound heal-
ing assay. This assay is a modified method for monitor-
ing cell movement that uses different-colored MCF7
cells. These cells are stably transfected with either
pEGFP (green) or pTomato (red) expression vectors. In
a mixed culture of MCF7-GFP cells transfected with
S100A14-siRNA and MCF7-Tomato cells transfected
with control siRNA, a scratch wound was filled in by
cell movements that consisted of red cells in the front
line followed by green cells (Figure 4C). Similar results
were obtained by using cells with a reverse combination
of siRNAs. The third system that we used was an assay
of cell invasion using a 3D-culture of tumor spheroids
in a collagen gel. After 3 days culture in this system,
MCF7 cells that were transfected with control siRNA
exhibited features of migrating cells, displaying finger-
like projections and satellite cells, while S100A14
knockdown cells did not exhibit any such features of
migrating cells (Figure 4D).Discussion
This report describes three major findings: 1) S100A14
and S100A16 expression is correlated to poor prognosis
in breast cancer patients; 2) The localization of these
proteins is limited to the plasma membrane along the
lateral surface of the cell, which may be due to their
interaction with actin; and 3) S100A14 and S100A16
promote the invasive activity of breast cancer cells. All
of these findings indicate that S100A14 and S100A16 ex-
pression augments the malignant phenotype of breast
cancer.


























































Figure 3 Interaction of the S100A14 protein with actin and analyses of its functional interaction with S100A16. A, An extract of MCF7
cells was immunoprecipitated (IP) with control rabbit IgG, anti-S100A14 or anti-actin antibodies. Precipitated and co-precipitated proteins were
detected by immunoblotting with anti-S100A14 and anti-actin antibodies. The following were added to the extracts prior to precipitation. CaCl2;
0 mM (lane 1), 0.5 mM (lane 2) or 2 mM (lane 3), or, 2 mM CaCl2 and 10 mM EDTA (lane 4). Arrows indicate actin and S100A14. B, Co-localization
of S100A14 with polymerized actin and S100A16 in MCF7 cells. Co-immunostaining with the anti-S100A14 antibody and a FITC-labeled second
antibody (green), and with rhodamine-conjugated phalloidin (red) showed colocalization of both S100A14 and actin along the cell membrane of
MCF7 cells (top). Co-localization of S100A14 and S100A16 was also confirmed in MCF7 cells (bottom). Scale bars; 20 μm. C, Analysis of the mRNA
expression of S100A14 and S100A16 in MCF7 cells transfected with siRNA for S100A14 or S100A16. Gene knockdown of S100A14 or S100A16 does
not affect the mRNA expression level of the other S100 protein in MCF7 cells. The relative mRNA expression levels were normalized to the GAPDH
mRNA expression level. Error bars, + SD, n=3. D, Effect of siRNA targeted against S100A14 or S100A16 on the expression of each protein. Western
blots of extracts of MCF7 cells transfected with siRNA targeted against S100A14 or S100A16 were probed with antibodies against S100A14, S100A16
and b-actin. E, Expression of S100A14 or S100A16 protein following knockdown of the counterpart molecule. Immunofluorescence analysis of
the protein expression and localization of S100A14 and S100A16 in MCF7 cells 48 h after transfection with siRNA targeted against each protein.
Scale bars; 10 μm.
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Figure 4 The effects of S100A14 and S100A16 knockdown on cancer cell invasion and motility. A, In vitro invasion assay using a Matrigel-
coated transmembrane. Invading MCF7 and SK-BR-7 cells were counted 24 h after seeding of knockdown cells (the error bar represent S.D., n=3).
B, Wound healing assay using MCF7 cells transfected with siRNA for S100A14or S100A16. The wound width was measured, and the distance over
which the cells had migrated 48 h after scratching was calculated (the error bars represent S.D., n=3). C, A dual-color wound healing assay using
MCF7 cells that were stably transfected with GFP or Tomato expression vectors that were further transfected with siRNA for S100A14 or control,
respectively. The white lines represent the migration fronts at 48 h after scratching of a mixed culture of cells on a confluent monolayer. Scale
bars; 50 μm. D, Confocal images of representative spheroids of MCF7 cells grown in a collagen gel for 48 h after transfection of S100A14 or
control siRNA. Scale bar; 50 μm.
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expression levels of S100A14 and S100A16, especially of
co-expression of the two proteins, were significantly cor-
related with factors associated with poor prognosis and
with a lower overall survival rate. There have been many
reports of S100A14 expression in a variety of cancers
[8,10,11,13,20-23], whereas S100A16 has not been well
analyzed in clinical cases [24]. In the studies of S100A14
expression, contrasting data regarding its relationship to
prognosis, which were based on immunohistochemical
methods of S100A14 expression, have been reported;
S100A14 expression was correlated with a poorer prog-
nosis in carcinomas of the breast, liver, and stomach
[8,9,25] and with a favorable prognosis in colorectal and
small intestinal carcinomas [10,11]. One possible reason
for these discrepancies is that S100A14 may be able to
interact with multiple target proteins such as HER2,
MMP2, P53 and receptor for advanced glycation end
products (RAGE) [9,12-15] that are involved in variouscellular functions, as is the case for other S100 family
members. Indeed, our immunohistochemical screening
on normal and neoplastic tissues indicates that the mo-
lecular functions of S100A14 and S100A16 proteins may
differ in different cell types depending on their protein
expression levels and their subcellular localization. There-
fore, these factors should be taken into consideration
when evaluating the expression and potential function of
these proteins in cancer cells. In this sense, the immuno-
histochemical criteria that we used for evaluation of
S100A14 and S100A16 positivity in breast cancers, which
evaluated the staining pattern and staining intensity of
these proteins based on their subcellular localization and
potential function in cytoskeletal organization may be a
more suitable method for evaluation of these proteins
than simply evaluation of total cellular expression of these
proteins.
A clinicopathological study of breast cancer was car-
ried out by Xu et al., which immunohistochemically
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ported that patient prognosis was poorer in cases in
which S100A14 and HER2 were co-expressed compared
to cases that did not express either protein. Because of
the close correlation between S100A14 and HER2 ex-
pression in breast cancer, the prognosis of S100A14-
positive patients could be affected by HER2 status when
prognosis was analyzed using standard statistical methods.
However, our multivariate analysis showed that expres-
sion of S100A14, and co-expression of S100A14 and
S100A16, are independent prognostic factors for breast
cancer. This is the first report in which the clinical sig-
nificance of S100A14 protein expression as an inde-
pendent prognostic factor in breast cancer has been
demonstrated. In addition, to our knowledge, clinico-
pathological studies of the expression of S100A16 (ex-
cept for reports of global expression profiles), or of the
co-expression of S100A14 and S100A16 in breast can-
cer patients have not been reported.
In the present study, the S100A16 protein showed
similar expression patterns to S100A14 both in terms
of clinical correlations and of cell membrane localization.
Our in vitro data indicated that S100A14 and S100A16
are dependent on each other for their membrane
localization; when either protein was knocked down,
the other protein was not expressed on the membrane
although there was no reduction in its mRNA expres-
sion level. Therefore, these proteins may require each
other for anchorage to the membrane. Indeed, Sapkota
et al. demonstrated an interaction between S100A14
and S100A16 proteins in an oral squamous cell carcinoma
cell line by using a co-immunoprecipitation method [17].
Thus, interaction between S100A14 and S100A16 proteins
may be the reason for the strong correlation of their ex-
pression in human breast cancer tissues. The mechan-
ism and function of their interaction, however, are
unknown. Thus, S100A14 and S100A16 proteins may
promote the malignant nature of breast cancer by act-
ing in cooperation with each other or with other bind-
ing proteins on the cell membrane.
The second major findings in this study is the protein
localization of S100A14 and S100A16 on the cell mem-
brane, which are commonly found both clinical and ex-
perimental studies. Our in vitro study provided a more
detailed subcellular localization of these proteins, indi-
cating that they are expressed along the lateral surface
of the membrane and at intercellular junctions in the
confluent state. These findings suggest that S100A14
and S100A16 might bind to membrane-associated pro-
teins in a similar manner as other S100 family proteins
such as S100A10 and A11, which bind to annexins
[26-28]. A pull-down assay and subsequent mass spec-
trometry analysis we previously performed have dem-
onstrated the binding of the S100A14 protein to actin,a major cytoskeletal protein (data not shown). Further-
more, double staining using the S100A14 antibody and
phalloidin indicated that S100A14 may bind to membrane-
localized polymerized actin, such as cortical actin. Two
other molecules; RAGE and HER2, have been identified
as binding proteins for S100A14 [9,15]. However, two
findings of the present study suggest that S100A14
anchorage to the cell membrane may be mediated by
actin assembled on the cell cortex rather than by RAGE
or HER2; 1) S100A14 is located at the inner (cytoplas-
mic) side of the cell membrane, indicating that in
these breast cancer cells it cannot be a ligand of a
membrane-bound receptor such as RAGE that has a
ligand binding region on the outside of the cell and 2)
the S100A14 protein is ubiquitously expressed in a
wide variety of normal, and neoplastic cells, including
squamous epithelial cells, which display no amplifica-
tion of HER2.
The third important finding of the present study is
the invasion-promoting activity of S100A14 and S100A16.
Our knockdown studies demonstrate that these molecules
can promote cell motility and invasive activity of breast
cancer cells. There have been some reports regarding the
contribution of S100A14 functions to the malignant na-
ture of cancer cells [8,9,13,15]. Although the molecular
mechanisms are not fully understood, S100A14 can
promote cancer cell invasion by regulating MMP2 tran-
scription in a p53-dependent manner and it can also
induce cell proliferation and apoptosis by binding to
RAGE, resulting in stimulation of RAGE-dependent
signaling cascades. Our findings indicate a novel mo-
lecular mechanism of S100A14 that may promote
cancer invasion by binding to actin to activate cell
movement. In addition, as shown in the dual-color
wound healing assay, most of the moving cells at the
migration front of a migrating population of cells were
S100A14 positive cells. In contrast, at the rear of this
front, cancer cells including S100A14-positive and-
negative cells appear to follow the migrating leader cells
by maintaining cell-cell attachments, whether they
express S100A14 protein or not. These cellular and mo-
lecular dynamics suggest that the movement of neo-
plastic epithelial cells requires not only binding of
S100A14 to cytoskeletal actin but also additional condi-
tions at the migrating front.
Conclusion
Our findings suggest that S100A14 and S100A16 protein
expression may be predictive biomarkers for poorer
prognosis of breast cancer patients. Because S100A14
and S100A16 can promote cancer cell motility and inva-
sion via modulation of cytoskeletal dynamics, these pro-
teins could be novel target molecules for therapeutic
strategies in breast cancer patients.
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Additional file 1: Figure S1. Absorption test of S100A14 and S100A16
antibodies mixed with their corresponding antigenic recombinant proteins.
A, Immunohistochemistry using paraffin sections of squamous epithelium of
skin and of breast cancer. B, Western blotting using an extract of MCF7 cells.
Additional file 2: Figure S2. Comparison of the gene knockdown
efficacy among siRNAs with three different sequences for each mRNA of
S100A14 and S100A16. After 48 h from transfection with siRNA, MCF7
cells on a culture side was stained according to the immunofluorescence
method. Scale bars; 20 μm (A) and 40 μm (B). The sequence of siRNA
were S100A14 No. 1: 5′-CCUUCUGAGCUACGGGACCUGGUCA-3′, S100A14
No. 2: 5′-GAGUUCAGGAGUUUCUGGGAGCUGA-3′, S100A14 No. 3: 5′-CCAAC
GCAGAGGAUGCUCAGGAAUU-3′, S100A16 No. 1: 5′-CCAAUCAUGAUGGGCG
CAUCAGCUU-3′, S100A16 No. 2: 5′-AAGGCAGUCAUUGUCCUGGUGGAAA-3′
and S100A16 No. 3: 5′-CAGGGAACCGGAAGGCUGCGGAUAA-3′.
Additional file 3: Figure S3. Immunohistochemical analysis of S100A14
protein expression in normal and cancerous tissues. The figures show
representative images of S100A14 protein expression. The subcellular
localization of this protein is different in normal tissues; it is in the membrane
in the epidermis, in both the membrane and the cytoplasm in the colon
and is in the cytoplasm in renal tubules (Upper figures). In cancers, the
expression and the localization of the S100A14 protein are different
depending on the tissue of origin (Lower figures). SqCC: squamous cell
carcinoma, RCC: renal cell carcinoma. The table shows the number of
various cancer cases with strong expression of the S100A14 protein as
assessed by using this immunohistochemical method. Scale bars; 500 μm.
Additional file 4: Video S1. Time-lapse video microscopy of MCF7 cells
stably transfected with GFP-tagged S100A14.
Additional file 5: Figure S4. The effects of S100A14 and S100A16
knockdown on in vitro cell growth of MCF7 and SK-BR-3 cells. Growth of
the cells was determined by a cell viability (XTT) assay after treatment
with siRNAs targeted towards S100A14, S100A16, or both proteins for
48 h (error bars represent S.D., n=3).
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